NASDAQ:SRRK Scholar Rock Q3 2026 Earnings Date & Estimates $43.72 +0.81 (+1.88%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more. Scholar Rock is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Scholar Rock in Q3 2026Scholar Rock is expected to post earnings of -$0.8472 per share on revenue of $304 thousand. In the same quarter a year earlier Scholar Rock reported -$0.90 per share. Scholar Rock last reported on August 6, 2026, posting -$0.84 per share and beating the -$0.8405 consensus estimate. Scholar Rock has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.8472Expected Revenue$304 thousandPrior-Year EPS-$0.90Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.84 (Beat by +$0.0005)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Scholar Rock Q3 2026 Earnings FAQ When does Scholar Rock report Q3 2026 earnings? Scholar Rock (NASDAQ:SRRK) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Scholar Rock's Q3 2026 earnings call? Scholar Rock's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Scholar Rock? Analysts expect Scholar Rock to post earnings of -$0.8472 per share for Q3 2026. How much revenue is Scholar Rock expected to report? The consensus revenue estimate for Scholar Rock is $304 thousand for Q3 2026. Scholar Rock Earnings HeadlinesScholar Rock Holding Corporation (NASDAQ:SRRK) Stock Rated "Moderate Buy" by Wall Street AnalystsNovember 3 at 2:29 AM | americanbankingnews.comScholar Rock (SRRK) Stock Could Trade At A Premium On Balance Sheet HopesOctober 30, 2026 | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 3 at 1:00 AM | Behind the Markets (Ad)Scholar Rock (NASDAQ:SRRK) Stock: Insider Srinivas Akkaraju Buys 146,970 SharesOctober 29, 2026 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Stock: Insider Srinivas Akkaraju Acquires 142,500 SharesOctober 29, 2026 | americanbankingnews.comScholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026October 20, 2026 | finance.yahoo.comSee More Scholar Rock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scholar Rock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scholar Rock and other key companies, straight to your email. Email Address About Scholar RockScholar Rock (NASDAQ:SRRK), Inc. is a biotechnology company focused on developing medicines that selectively target growth factors in the transforming growth factor beta (TGF-β) superfamily. The company’s research is intended to address serious diseases in which these signaling pathways play an important role, including neuromuscular and metabolic conditions. Scholar Rock’s lead investigational product is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that limits muscle growth. The therapy has been studied primarily for spinal muscular atrophy, a genetic neuromuscular disorder, and the company has also evaluated its potential in other conditions involving muscle function. Scholar Rock continues to advance apitegromab and additional discovery- and clinical-stage programs targeting related biological pathways. Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock conducts research and clinical development activities in collaboration with investigators and healthcare organizations in the United States and other international markets. The company is led by President and Chief Executive Officer Jay Backstrom, M.D.View Scholar Rock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings BeatCheck Point's Turnaround Could Be Closer Than Investors ThinkTempus AI Surges on Earnings Beat, But Can the Rally Last? Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
